本文選題：子宮內(nèi)膜癌 + BRCAl��； 參考：《廣西醫(yī)科大學(xué)》2014年碩士論文

【摘要】：目的： 檢測乳腺癌易感基因1（BRCAl）及表皮生長因子（EGFR）在正常子宮內(nèi)膜、子宮內(nèi)膜不典型增生、子宮內(nèi)膜癌中（Endometrial Cancer,EC）的表達(dá)，探討它們與子宮內(nèi)膜癌發(fā)生發(fā)展的關(guān)系。 方法： 采用免疫組化鏈霉菌抗生物素蛋白-過氧化物酶(Streptavidin-peroxidase,S-P)法檢測BRCAl、EGFR在正常子宮內(nèi)膜、子宮內(nèi)膜不典型增生、子宮內(nèi)膜癌組織中的表達(dá)情況,并結(jié)合年齡、絕經(jīng)與否、手術(shù)病理分期、組織學(xué)分級、淋巴結(jié)轉(zhuǎn)移、肌層浸潤深度等臨床病理特征及隨訪資料進行分析。 結(jié)果： （1）BRCAl在正常子宮內(nèi)膜、子宮內(nèi)膜不典型增生、子宮內(nèi)膜癌組織中的陽性表達(dá)率分別為90％(36/40)；66.7%(20/30)；31.7%(19/60)，各組間差異有統(tǒng)計學(xué)意義(P0.05)；EGFR在正常子宮內(nèi)膜、子宮內(nèi)膜不典型增生、子宮內(nèi)膜癌組織中的陽性表達(dá)率分別為30％(12/40)；36.7%(11/30)；73.3%(44/60)。各組間差異有統(tǒng)計學(xué)意義(P0.05)。 （2）子宮內(nèi)膜癌中BRCAl基因的陽性表達(dá)率在不同年齡組間，絕經(jīng)與否組間差異有統(tǒng)計學(xué)意義(P0.05)。BRCA1陽性表達(dá)與組織學(xué)分級、手術(shù)病理分期、淋巴結(jié)轉(zhuǎn)移、肌層浸潤深度有關(guān)（P0.05）。隨著組織學(xué)分級的增加，BRCAl的表達(dá)降低(P0.05)。 （3）EGFR的陽性表達(dá)與絕經(jīng)與否、手術(shù)病理分期、淋巴結(jié)轉(zhuǎn)移、肌層浸潤深度有關(guān)（P均0.05），而與年齡、組織學(xué)分級無關(guān)（P＞0.05）。 （4）子宮內(nèi)膜癌中BRCAl、EGFR之間的表達(dá)呈負(fù)相關(guān)(r=-0.319,P=0.013＜0.05)。 （5）Kplan-Meier生存分析： BRCA1、EGFR的表達(dá)及組織學(xué)分級與子宮內(nèi)膜癌預(yù)后有關(guān)(P0.05)。 （6）Cox回歸模型分析顯示： EGFR與組織學(xué)分級為影響子宮內(nèi)膜癌預(yù)后的因素(P0.05)。 結(jié)論： 1. BRCA1在子宮內(nèi)膜癌中呈低表達(dá)，與子宮內(nèi)膜癌的組織學(xué)分級、手術(shù)病理分期、浸潤深度、淋巴結(jié)轉(zhuǎn)移有關(guān)，可能可以作為預(yù)測腫瘤的惡性程度及不良預(yù)后的指標(biāo)。 2.EGFR在子宮內(nèi)膜癌中呈高表達(dá)，與子宮內(nèi)膜癌的手術(shù)病理分期、浸潤深度、淋巴結(jié)轉(zhuǎn)移有關(guān)，可能可以作為評估腫瘤的惡性程度及預(yù)后的指標(biāo)。 3.BRCA1和EGFR在子宮內(nèi)膜癌中的表達(dá)呈負(fù)相關(guān)，EGFR陽性表達(dá)越高，BRCA1陽性表達(dá)則越低。兩者可能共同參與了子宮內(nèi)膜癌的疾病惡性進展過程及不良預(yù)后，，對子宮內(nèi)膜癌的預(yù)后及術(shù)后的治療可能有一定的指導(dǎo)作用。
[Abstract]:Objective: To detect the expression of breast cancer susceptibility gene (BRCAl) and epidermal growth factor (EGFR) in normal endometrium, endometrial atypical hyperplasia and endometrial carcinoma, and to explore the relationship between them and the occurrence and development of endometrial carcinoma. Methods: The expression of BRCAl-EGFR in normal endometrium, endometrial atypical hyperplasia, endometrial carcinoma and age, menopausal or not was detected by immunohistochemical streptavidin-peroxidaseS-Phosphorimetric method. The expression of BRCAl-EGFR in normal endometrium, endometrial atypical hyperplasia and endometrial carcinoma was determined by age, menopause or not, and the stage of operation and pathology. Histological grade, lymph node metastasis, depth of myometrial invasion and other clinicopathological features and follow-up data were analyzed. Results: The positive expression rates of BRCAl in normal endometrium, endometrial atypical hyperplasia, endometrial carcinoma and endometrial carcinoma were 90 / 36 / 40 / 66.7 and 20 / 30 / 31.7 / 19 / 60, respectively. There were significant differences between the two groups in the expression of EGFR in normal endometrium and endometrial atypical hyperplasia. The positive expression rates in endometrial carcinoma were 30 / 12 / 40 / 36.7 / 11 / 30 / 73.3 / 40 / 60 respectively. The difference among the groups was statistically significant (P 0.05). (2) the positive expression rate of BRCAl gene in endometrial carcinoma was significantly different between postmenopausal and postmenopausal groups. The positive expression of BRCAl gene was correlated with histological grade, surgical stage, lymph node metastasis and depth of myometrium invasion. With the increase of histological grade, the expression of BRCAl decreased (P 0.05). The positive expression of EGFR was correlated with menopausal stage, pathological stage, lymph node metastasis and depth of myometrial invasion (P < 0.05), but had no correlation with age and histological grade (P > 0.05). (4) there was a negative correlation between the expression of BRCAlN and EGFR in endometrial carcinoma. Kplan-Meier survival analysis: the expression and histological grade of EGFR in BRCA1 were related to the prognosis of endometrial carcinoma (P 0.05). EGFR and histological grade were the factors influencing the prognosis of endometrial carcinoma (P 0.05). Conclusion: 1. The low expression of BRCA1 in endometrial carcinoma is related to histological grade, pathological stage, depth of invasion and lymph node metastasis, which may be used as an index to predict the malignant degree and poor prognosis of endometrial carcinoma. The high expression of 2.EGFR in endometrial carcinoma is related to the pathological stage, depth of invasion and lymph node metastasis of endometrial carcinoma. It may be used as an index to evaluate the malignant degree and prognosis of endometrial carcinoma. The expression of 3.BRCA1 and EGFR in endometrial carcinoma was negatively correlated. The higher the positive expression of 3.BRCA1 and EGFR was, the lower the positive expression of BRCA1 was. Both of them may be involved in the malignant progression and poor prognosis of endometrial carcinoma, which may be helpful to the prognosis and postoperative treatment of endometrial carcinoma.
【學(xué)位授予單位】：廣西醫(yī)科大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2014
【分類號】：R737.33

【參考文獻(xiàn)】

相關(guān)期刊論文 前4條

1 鄧文國,曾瑞萍,蔣瑋瑩,杜傳書;BRCA1基因在原發(fā)性卵巢癌組織中突變的研究[J];癌癥;1999年05期

2 付欣鴿;王振華;李鋒;胡文浩;米開·熱木;蔣金芳;李洪安;;110例維吾爾族及漢族乳腺癌中BRCA1基因突變及P53蛋白表達(dá)的研究[J];中國組織化學(xué)與細(xì)胞化學(xué)雜志;2007年03期

3 趙時梅,姚波,嚴(yán)龍,黃玲,陳瓊,黃武國,林海蘭;乳腺癌BRCA1蛋白表達(dá)與DNA定量分析的臨床研究[J];廣西醫(yī)學(xué);2005年03期

4 陳晶晶;陳柯;王曉秋;;子宮內(nèi)膜癌組織中Id-1、VEGF-C和EGFR的表達(dá)及臨床意義[J];臨床與實驗病理學(xué)雜志;2010年02期

本文編號：1820158